Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01579565 · ClinicalTrials.gov registry record · Phase 3
Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
A Phase 3 study of Intraocular Lens Replacement, sponsored by Omeros Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 416
- Enrollment target
- 14
- Study locations
NCT01579565 is a Phase 3 study of Intraocular Lens Replacement that has completed, run by Omeros Corporation. The registered enrollment target is 416 participants. The trial reports 14 study locations across 11 states.
The verdict
NCT01579565, a Phase 3 study of Intraocular Lens Replacement, has completed, sponsored by Omeros Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 416 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to determine the safety, efficacy and pharmacokinetics of OMS302 (the study drug) for maintaining intraoperative mydriasis and preventing post operative pain in individuals undergoing Intraocular Lens Replacement (ILR) surgery.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG OMS302
Study Locations (14)
Texas
- - Austin
- - Houston
- - San Antonio
Missouri
- - St Louis
- - Washington
Arizona
- - Chandler
California
- - Los Angeles
Florida
- - Fort Myers
Massachusetts
- - Boston
New Mexico
- - Albuquerque
New York
- - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01579565
The ClinicalTrials.gov registry entry for NCT01579565 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Omeros Corporation, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intraocular Lens Replacement appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01579565 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Texas, Missouri, Arizona.
Frequently Asked Questions
What is clinical trial NCT01579565 about?
NCT01579565 is a clinical study titled "Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification". The purpose of this study is to determine the safety, efficacy and pharmacokinetics of OMS302 (the study drug) for maintaining intraoperative mydriasis and preventing post operative pain in individuals undergoing Intraocular Lens Replacement (ILR) surgery.
What is the current status of trial NCT01579565?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 416 participants. The study started on 2012-04. Estimated completion is 2013-01.
What conditions does trial NCT01579565 study?
This clinical trial studies the following conditions: Intraocular Lens Replacement.
What interventions are being tested in trial NCT01579565?
The interventions under investigation include: Placebo (DRUG), OMS302 (DRUG).
Who is sponsoring clinical trial NCT01579565?
This trial is sponsored by Omeros Corporation, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01579565 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.